Latest Breaking News On - சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம் - Page 15 : comparemela.com

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo Statistically significant OS benefit in efti group observed in pre-defined patient groups: +7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age

Region flamandeSan antonioUnited statesNew south walesHans wildiersKaplan meyerFrederic triebelTim mccarthyMarc voigtImmutep limitedUniversity hospital leuvenAustralian securities exchangeOverall survivalAustralian eastern daylight timeSan antonio breast cancer symposiumEfficacy results